Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer Journal Article

Authors: Friedman, C. F.; Snyder Charen, A.; Zhou, Q.; Carducci, M. A.; Buckley De Meritens, A.; Corr, B. R.; Fu, S.; Hollmann, T. J.; Iasonos, A.; Konner, J. A.; Konstantinopoulos, P. A.; Modesitt, S. C.; Sharon, E.; Aghajanian, C.; Zamarin, D.
Article Title: Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Abstract: BACKGROUND: There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for programmed death ligand 1 (PD-L1) positive cervical cancer with a modest response rate. This is the first study to report the efficacy and safety of the PD-L1 antibody atezolizumab in combination with bevacizumab in advanced cervical cancer. METHODS: We report the results from a phase II, open-label, multicenter study (NCT02921269). Patients with advanced cervical cancer were treated with bevacizumab 15 mg/kg intravenous every 3 weeks and atezolizumab 1200 mg intravenous every 3 weeks. The primary objective was to measure the objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: In the total evaluable population (n=10), zero patients achieved an objective response as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1, resulting in a confirmed ORR of 0%. Of note, there were two patients who achieved an unconfirmed PR. The DCR by RECIST V.1.1 was 60% (0% complete response, 0% partial response, 60% stable disease). Median PFS was 2.9 months (95% CI, 1.8 to 6) and median OS was 8.9 months (95% CI, 3.4 to 21.9). Safety results were generally consistent with the known safety profile of both drugs, notably with two high-grade neurologic events. CONCLUSIONS: The combination of bevacizumab and atezolizumab did not meet the predefined efficacy endpoint, as addition of bevacizumab to PD-L1 blockade did not appear to enhance the ORR in cervical cancer. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords: drug therapy; combination; tumor biomarkers; female; programmed cell death 1 receptor; genital neoplasms
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 8
Issue: 2
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2020-07-01
Start Page: e001126
Language: English
DOI: 10.1136/jitc-2020-001126
PUBMED: 33004542
PROVIDER: scopus
PMCID: PMC7534695
Notes: Article -- Export Date: 2 November 2020 -- Source: Scopus
Citation Impact
MSK Authors
  1. Jason Konner
    120 Konner
  2. Dmitriy Zamarin
    130 Zamarin
  3. Qin Zhou
    167 Zhou
  4. Alexia Elia Iasonos
    249 Iasonos